Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Spondylarthritis | 7 | 2018 | 174 | 2.28 | Why? |
| Arthritis, Rheumatoid | 18 | 2021 | 2043 | 1.39 | Why? |
| Rheumatology | 12 | 2021 | 1213 | 1.34 | Why? |
| Hip Fractures | 3 | 2018 | 667 | 0.89 | Why? |
| Rheumatic Diseases | 11 | 2021 | 2675 | 0.82 | Why? |
| Osteoporotic Fractures | 2 | 2018 | 175 | 0.72 | Why? |
| Pelvic Bones | 1 | 2017 | 26 | 0.72 | Why? |
| Biological Products | 8 | 2020 | 2331 | 0.64 | Why? |
| Myositis | 1 | 2019 | 185 | 0.62 | Why? |
| Biological Factors | 2 | 2019 | 276 | 0.62 | Why? |
| Arthritis, Psoriatic | 4 | 2020 | 625 | 0.59 | Why? |
| Antirheumatic Agents | 10 | 2021 | 3023 | 0.59 | Why? |
| Antibodies | 2 | 2019 | 846 | 0.58 | Why? |
| Musculoskeletal Diseases | 5 | 2021 | 646 | 0.56 | Why? |
| Weight Loss | 2 | 2017 | 826 | 0.55 | Why? |
| Biological Therapy | 1 | 2019 | 456 | 0.54 | Why? |
| Osteoporosis | 1 | 2017 | 410 | 0.47 | Why? |
| Hospital Units | 1 | 2019 | 1017 | 0.45 | Why? |
| Fractures, Bone | 1 | 2017 | 487 | 0.45 | Why? |
| Interdisciplinary Communication | 1 | 2019 | 1425 | 0.43 | Why? |
| Rheumatologists | 3 | 2018 | 346 | 0.40 | Why? |
| Medication Adherence | 4 | 2018 | 1270 | 0.35 | Why? |
| Scleroderma, Systemic | 3 | 2017 | 583 | 0.31 | Why? |
| Gout | 2 | 2017 | 85 | 0.30 | Why? |
| Periodicals as Topic | 1 | 2017 | 1492 | 0.27 | Why? |
| Spondylarthropathies | 2 | 2020 | 163 | 0.25 | Why? |
| Spain | 10 | 2019 | 15545 | 0.22 | Why? |
| Obesity | 4 | 2020 | 7388 | 0.21 | Why? |
| Exercise Therapy | 3 | 2018 | 976 | 0.21 | Why? |
| Age Factors | 3 | 2020 | 21039 | 0.21 | Why? |
| Patients | 2 | 2018 | 1167 | 0.20 | Why? |
| Scleroderma, Limited | 1 | 2018 | 10 | 0.19 | Why? |
| Incidence | 3 | 2018 | 25622 | 0.19 | Why? |
| Scleroderma, Diffuse | 1 | 2018 | 20 | 0.19 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 9335 | 0.19 | Why? |
| Multimedia | 1 | 2018 | 14 | 0.19 | Why? |
| Suburban Population | 1 | 2017 | 70 | 0.18 | Why? |
| Connective Tissue Diseases | 1 | 2020 | 187 | 0.18 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 2019 | 393 | 0.18 | Why? |
| Benchmarking | 2 | 2019 | 627 | 0.17 | Why? |
| Osteoprotegerin | 1 | 2016 | 32 | 0.17 | Why? |
| Transition to Adult Care | 1 | 2017 | 56 | 0.16 | Why? |
| Systole | 1 | 2017 | 252 | 0.16 | Why? |
| Practice Patterns, Physicians' | 4 | 2019 | 4927 | 0.15 | Why? |
| Joints | 1 | 2016 | 97 | 0.15 | Why? |
| Observational Studies as Topic | 3 | 2019 | 1887 | 0.15 | Why? |
| Proportional Hazards Models | 2 | 2019 | 6543 | 0.15 | Why? |
| Echocardiography, Doppler | 1 | 2017 | 269 | 0.15 | Why? |
| Patient Satisfaction | 2 | 2018 | 2517 | 0.14 | Why? |
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 245 | 0.14 | Why? |
| Osteoarthritis, Knee | 1 | 2017 | 158 | 0.14 | Why? |
| Evidence-Based Medicine | 2 | 2018 | 3228 | 0.14 | Why? |
| Epidemiologic Methods | 1 | 2018 | 392 | 0.13 | Why? |
| Decision Support Techniques | 2 | 2018 | 903 | 0.13 | Why? |
| Carotid Artery Diseases | 1 | 2017 | 251 | 0.13 | Why? |
| Biosimilar Pharmaceuticals | 1 | 2017 | 205 | 0.13 | Why? |
| Gastroenterologists | 1 | 2017 | 259 | 0.13 | Why? |
| Focus Groups | 4 | 2018 | 811 | 0.13 | Why? |
| Drug Utilization | 1 | 2019 | 619 | 0.13 | Why? |
| Self-Management | 1 | 2019 | 546 | 0.13 | Why? |
| Quality Control | 1 | 2017 | 628 | 0.12 | Why? |
| Delphi Technique | 4 | 2018 | 1257 | 0.12 | Why? |
| Humans | 50 | 2021 | 930598 | 0.12 | Why? |
| Patient Care Planning | 1 | 2017 | 582 | 0.12 | Why? |
| Hospitals, Public | 1 | 2019 | 774 | 0.12 | Why? |
| Consensus | 5 | 2018 | 6345 | 0.12 | Why? |
| Glucocorticoids | 4 | 2021 | 4431 | 0.12 | Why? |
| Risk Factors | 12 | 2020 | 71621 | 0.12 | Why? |
| Kaplan-Meier Estimate | 2 | 2019 | 4260 | 0.12 | Why? |
| Weather | 1 | 2018 | 581 | 0.12 | Why? |
| Longitudinal Studies | 5 | 2017 | 9893 | 0.11 | Why? |
| Terminology as Topic | 1 | 2017 | 546 | 0.11 | Why? |
| Hypertension, Pulmonary | 2 | 2017 | 970 | 0.11 | Why? |
| Checklist | 1 | 2017 | 714 | 0.11 | Why? |
| Overweight | 1 | 2017 | 916 | 0.11 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.10 | Why? |
| Middle Aged | 25 | 2021 | 270681 | 0.10 | Why? |
| Registries | 5 | 2021 | 12327 | 0.10 | Why? |
| Pulmonary Artery | 1 | 2017 | 803 | 0.10 | Why? |
| Inflammatory Bowel Diseases | 2 | 2018 | 3209 | 0.10 | Why? |
| Multivariate Analysis | 5 | 2020 | 5440 | 0.10 | Why? |
| Health Surveys | 2 | 2018 | 2841 | 0.10 | Why? |
| Male | 29 | 2021 | 367725 | 0.10 | Why? |
| Female | 29 | 2021 | 380317 | 0.10 | Why? |
| Health Knowledge, Attitudes, Practice | 5 | 2018 | 8811 | 0.10 | Why? |
| Aged | 19 | 2021 | 215776 | 0.10 | Why? |
| Noncommunicable Diseases | 1 | 2018 | 934 | 0.09 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.09 | Why? |
| Early Diagnosis | 1 | 2017 | 2443 | 0.09 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.09 | Why? |
| Lipids | 1 | 2015 | 1079 | 0.09 | Why? |
| Gastroenterology | 1 | 2019 | 1352 | 0.09 | Why? |
| Motivation | 1 | 2018 | 1640 | 0.09 | Why? |
| Disease Management | 4 | 2018 | 6841 | 0.08 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.08 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.08 | Why? |
| Neurology | 1 | 2019 | 1613 | 0.08 | Why? |
| Fatigue | 1 | 2018 | 2479 | 0.08 | Why? |
| Sex Factors | 3 | 2020 | 11014 | 0.08 | Why? |
| Alcohol Drinking | 1 | 2017 | 1663 | 0.08 | Why? |
| Europe | 5 | 2021 | 12702 | 0.07 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.07 | Why? |
| Seasons | 1 | 2018 | 4071 | 0.07 | Why? |
| Immunosuppressive Agents | 2 | 2020 | 6331 | 0.07 | Why? |
| Depression | 2 | 2021 | 14116 | 0.07 | Why? |
| Retrospective Studies | 8 | 2019 | 105322 | 0.07 | Why? |
| Ultrasonography | 2 | 2017 | 4409 | 0.07 | Why? |
| Vitamin D Deficiency | 1 | 2017 | 1782 | 0.07 | Why? |
| Chi-Square Distribution | 2 | 2017 | 961 | 0.07 | Why? |
| Adult | 18 | 2020 | 244371 | 0.06 | Why? |
| Mobile Applications | 1 | 2019 | 3032 | 0.06 | Why? |
| Anxiety | 2 | 2021 | 17311 | 0.06 | Why? |
| Dermatology | 1 | 2019 | 1999 | 0.06 | Why? |
| Echocardiography | 1 | 2017 | 3661 | 0.06 | Why? |
| Aged, 80 and over | 6 | 2018 | 88759 | 0.06 | Why? |
| Logistic Models | 4 | 2020 | 9089 | 0.06 | Why? |
| Patient Acceptance of Health Care | 1 | 2021 | 5002 | 0.06 | Why? |
| Treatment Outcome | 6 | 2017 | 51732 | 0.06 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.05 | Why? |
| Polymyalgia Rheumatica | 1 | 2020 | 64 | 0.05 | Why? |
| Exercise | 1 | 2021 | 6771 | 0.05 | Why? |
| Cardiovascular Diseases | 4 | 2020 | 11497 | 0.05 | Why? |
| Health Status Disparities | 1 | 2018 | 4072 | 0.05 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.05 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.05 | Why? |
| Attitude of Health Personnel | 4 | 2018 | 4741 | 0.05 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2020 | 1380 | 0.05 | Why? |
| Cross-Sectional Studies | 7 | 2021 | 53120 | 0.05 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.05 | Why? |
| DNA Topoisomerases, Type I | 1 | 2018 | 86 | 0.04 | Why? |
| Surveys and Questionnaires | 4 | 2019 | 43792 | 0.04 | Why? |
| Prognosis | 5 | 2020 | 32490 | 0.04 | Why? |
| Raynaud Disease | 1 | 2018 | 86 | 0.04 | Why? |
| Infusions, Subcutaneous | 1 | 2016 | 36 | 0.04 | Why? |
| Acute-Phase Proteins | 1 | 2018 | 177 | 0.04 | Why? |
| Diet Therapy | 1 | 2017 | 66 | 0.04 | Why? |
| Sjogren's Syndrome | 1 | 2020 | 284 | 0.04 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| Poisson Distribution | 1 | 2018 | 348 | 0.04 | Why? |
| Autoantibodies | 2 | 2018 | 2094 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2018 | 647 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Health Impact Assessment | 1 | 2018 | 181 | 0.04 | Why? |
| Carotid Intima-Media Thickness | 1 | 2017 | 179 | 0.04 | Why? |
| Nuclear Proteins | 1 | 2018 | 321 | 0.04 | Why? |
| Prednisone | 1 | 2020 | 652 | 0.04 | Why? |
| Factor Analysis, Statistical | 1 | 2018 | 538 | 0.04 | Why? |
| Diuretics | 1 | 2017 | 326 | 0.04 | Why? |
| Patient Reported Outcome Measures | 1 | 2021 | 912 | 0.04 | Why? |
| Diabetic Angiopathies | 1 | 2017 | 146 | 0.04 | Why? |
| Qualitative Research | 2 | 2017 | 4337 | 0.03 | Why? |
| Janus Kinase Inhibitors | 1 | 2020 | 682 | 0.03 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.03 | Why? |
| Uric Acid | 1 | 2017 | 285 | 0.03 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.03 | Why? |
| Early Medical Intervention | 1 | 2017 | 487 | 0.03 | Why? |
| Intestinal Diseases | 1 | 2017 | 231 | 0.03 | Why? |
| Protective Factors | 1 | 2020 | 1720 | 0.03 | Why? |
| Comprehension | 1 | 2017 | 259 | 0.03 | Why? |
| Methotrexate | 1 | 2018 | 471 | 0.03 | Why? |
| Time Factors | 4 | 2018 | 31397 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Expert Testimony | 1 | 2017 | 658 | 0.03 | Why? |
| Remission Induction | 1 | 2017 | 950 | 0.03 | Why? |
| Vasculitis | 1 | 2020 | 691 | 0.03 | Why? |
| Portugal | 1 | 2018 | 1265 | 0.03 | Why? |
| Multimorbidity | 1 | 2018 | 703 | 0.03 | Why? |
| Societies, Medical | 2 | 2020 | 6907 | 0.03 | Why? |
| Metabolic Diseases | 1 | 2018 | 505 | 0.03 | Why? |
| Occupations | 1 | 2018 | 733 | 0.03 | Why? |
| Pyrroles | 1 | 2015 | 292 | 0.03 | Why? |
| Sweden | 1 | 2018 | 1969 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Psychometrics | 1 | 2018 | 1269 | 0.03 | Why? |
| Young Adult | 5 | 2020 | 93724 | 0.03 | Why? |
| Metformin | 1 | 2017 | 640 | 0.03 | Why? |
| Myocardial Ischemia | 1 | 2017 | 781 | 0.03 | Why? |
| Linear Models | 1 | 2016 | 1914 | 0.03 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 1454 | 0.03 | Why? |
| Interpersonal Relations | 1 | 2018 | 926 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
| Radiography | 1 | 2017 | 1576 | 0.02 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.02 | Why? |
| Chronic Pain | 1 | 2018 | 736 | 0.02 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.02 | Why? |
| Cerebrovascular Disorders | 1 | 2017 | 1040 | 0.02 | Why? |
| Netherlands | 1 | 2018 | 3533 | 0.02 | Why? |
| Piperidines | 1 | 2015 | 795 | 0.02 | Why? |
| Life Style | 1 | 2021 | 2708 | 0.02 | Why? |
| Drug Prescriptions | 1 | 2016 | 1062 | 0.02 | Why? |
| Telemedicine | 1 | 2019 | 25032 | 0.02 | Why? |
| Prospective Studies | 3 | 2017 | 43301 | 0.02 | Why? |
| Adolescent | 4 | 2020 | 86841 | 0.02 | Why? |
| Health Care Surveys | 1 | 2017 | 2942 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Needs Assessment | 1 | 2017 | 2352 | 0.02 | Why? |
| Physician-Patient Relations | 1 | 2017 | 1266 | 0.02 | Why? |
| Pyrimidines | 1 | 2015 | 1557 | 0.02 | Why? |
| Bariatric Surgery | 1 | 2017 | 1298 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| Perception | 1 | 2017 | 2827 | 0.02 | Why? |
| Lung Diseases, Interstitial | 1 | 2017 | 1476 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2019 | 3129 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Kidney Diseases | 1 | 2017 | 1434 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Emotions | 1 | 2018 | 2418 | 0.02 | Why? |
| Ambulatory Care Facilities | 1 | 2017 | 2063 | 0.02 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.02 | Why? |
| Protein Kinase Inhibitors | 1 | 2015 | 1585 | 0.02 | Why? |
| Lung Diseases | 1 | 2018 | 2361 | 0.02 | Why? |
| Hypoglycemic Agents | 1 | 2017 | 2165 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.02 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Canada | 1 | 2017 | 6018 | 0.02 | Why? |
| Australia | 1 | 2017 | 6306 | 0.02 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.02 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.02 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.01 | Why? |
| Germany | 1 | 2018 | 9196 | 0.01 | Why? |
| Health Care Rationing | 1 | 2017 | 2558 | 0.01 | Why? |
| Renal Insufficiency, Chronic | 1 | 2017 | 2654 | 0.01 | Why? |
| Pediatrics | 1 | 2017 | 2969 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| France | 1 | 2018 | 12074 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Chronic Disease | 1 | 2015 | 5139 | 0.01 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.01 | Why? |
| Internet | 1 | 2018 | 6204 | 0.01 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.01 | Why? |
| Heart Diseases | 1 | 2017 | 3503 | 0.01 | Why? |
| Communication | 1 | 2017 | 5206 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2016 | 17020 | 0.01 | Why? |
| United Kingdom | 1 | 2018 | 18046 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2015 | 10649 | 0.01 | Why? |
| Hypertension | 1 | 2017 | 8895 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2017 | 8207 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.01 | Why? |
| Italy | 1 | 2017 | 38444 | 0.01 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.01 | Why? |
| Neoplasms | 1 | 2017 | 17251 | 0.01 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.01 | Why? |